½ÃÀ庸°í¼­
»óǰÄÚµå
1454740

¼¼°èÀÇ ±¸Á¶Àû ½ÉÁúȯ¿ë ±â±â ½ÃÀå : Á¦Ç°º°, ½Ã¼úº°, ÃÖÁ¾ ¿ëµµº° ¿¹Ãø(2024-2032³â)

Structural Heart Devices Market - By Product (Heart Valve Devices, Occluders & Delivery Systems, Annuloplasty Rings), By Procedure (Replacement, Repair), By End-use (Hospitals, ASC, Cardiac Catheterization Labs) - Global Forecast, 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 220 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

±¸Á¶Àû ½ÉÁúȯ¿ë ±â±â ½ÃÀå ±Ô¸ð´Â Àû¿ë ¹üÀ§ È®´ë¿Í Áö¼ÓÀûÀÎ ½ÅÁ¦Ç° °³¹ß·Î ÀÎÇØ 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 8.8%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

±¸Á¶Àû ½ÉÀåÁúȯ¿ë ÀåÄ¡´Â ÆÇ¸· ±³Ã¼ ¹× ¼öº¹°ú °°Àº ÀüÅëÀûÀÎ ½Ã¼ú»Ó¸¸ ¾Æ´Ï¶ó ½É¹æÁ߰ݰá¼ÕÁõ(ASD), ½É¹æ¼¼µ¿(PFO), ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â¼ú(LAAC) µî ´Ù¾çÇÑ ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀåÄ¡ ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀº »õ·Î¿î Àç·á, °³¼±µÈ Àü´Þ ½Ã½ºÅÛ ¹× Çâ»óµÈ À̹Ì¡ ±â¼úÀÇ °³¹ß·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 3¿ù, Abbott´Â ÀÌÀü ¸ðµ¨¿¡¼­ ¸î °¡Áö °³¼±µÈ ÃֽйöÀüÀÇ ³ªºñÅç ½ÉÀåÆÇ¸· ±â¼úÀ» ¹Ì±¹¿¡¼­ Ãâ½ÃÇß½À´Ï´Ù. È¿°ú, ¾ÈÀü¼º ¹× °á°ú¸¦ °³¼±ÇÏ´Â ÀÌ·¯ÇÑ ½ÅÁ¦Ç° °³¹ßÀº Àü ¼¼°èÀûÀ¸·Î ±¸Á¶Àû ½ÉÀå Áúȯ¿ë ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

»ê¾÷Àº Á¦Ç°, ±â¼ú, ÃÖÁ¾ ¿ëµµ, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°º°·Î´Â 2024-2032³â 9.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµÇ´Â °í¸®Çü ¸µ ½ÃÀå Á¡À¯À²ÀÌ °¡Àå Å« °ßÀÎÂ÷ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ¸µÀº ½ÉÀå ÆÇ¸·ÀÇ ¼ö¸® ¹× ±³Ã¼, ƯÈ÷ ½Â¸ðÆÇ¸· ¹× »ï÷ÆÇ¸· ¼ö¼ú¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ½ÉÀå ÆÇ¸·ÁõÀÇ À¯º´·ü Áõ°¡¿Í ÃÖ¼Ò Ä§½À ¼ö¼ú ±â¼úÀÇ Ã¤Åà Áõ°¡´Â ½ÉÀå ÆÇ¸·ÀÇ ±â´É°ú ³»±¸¼ºÀ» Çâ»ó½Ã۱â À§ÇØ ½ÉÀå ÆÇ¸·¿¡ ±¸Á¶Àû ÁöÁö·ÂÀ» Á¦°øÇÏ´Â °í¸®Çü ¸µ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ¸µÀÇ µðÀÚÀÎ, Àç·á ¹× ±â¼ú ¹ßÀüµµ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµ Ãø¸é¿¡¼­ ½ÉÀå Ä«Å×ÅÍ °Ë»ç½Ç ºÎ¹® ±¸Á¶Àû ½ÉÀå Áúȯ¿ë ±â±â ½ÃÀåÀº 2023³â »ó´çÇÑ ¼öÀÍÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2032³â±îÁö 9.1%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ½ÉÀå Ä«Å×ÅÍ °Ë»ç½ÇÀº °æÇÇÀû ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR)°ú °æÇÇÀû ½Â¸ðÆÇ¸· ġȯ¼ú(TMVR)°ú °°Àº ±¸Á¶Àû ½ÉÀå Áúȯ¿¡ ´ëÇÑ ÃÖ¼Ò Ä§½ÀÀû ½Ã¼úÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÃÖ¼Ò Ä§½ÀÀû Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ·¯ÇÑ Àü¹® ½Ã¼³¿¡¼­ ±¸Á¶Àû ½ÉÁúȯ¿ë ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Áö¿ªÀû »óȲÀ» °í·ÁÇÒ ¶§, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±¸Á¶Àû ½ÉÀå Áúȯ ÀåÄ¡ »ê¾÷Àº °í·ÉÈ­¿Í »ýȰ½À°ü º¯È­¿¡ µû¸¥ ½ÉÇ÷°ü Áúȯ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î 2024³âºÎÅÍ 2032³â±îÁö 9.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, °æÁ¦ »óȲÀÇ °³¼±°ú ÀÇ·áºñ ÁöÃâ Áõ°¡´Â ÀÌ Áö¿ª Àüü¿¡¼­ ÷´Ü ½ÉÀå ½Ã¼úÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú Áß±¹, Àεµ, ÀϺ», Çѱ¹ ¹× ±âŸ ±¹°¡µéÀº ½ÉÀå ±¸Á¶ ÀåÄ¡ Á¦Á¶¾÷üÀÇ Áß¿äÇÑ °ÅÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ÀÎÇÁ¶óÀÇ ¹ßÀü, Á¤±³ÇÑ ÀÇ·á ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼º, ¼÷·ÃµÈ ÀÇ·á Àη Áõ°¡´Â ÀÌ Áö¿ª ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©£¦°úÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
  • °¡°Ý ºÐ¼®, 2023³â
  • »óȯ ½Ã³ª¸®¿À
  • ±ÔÁ¦ »óȲ
  • ±â¼úÀû Àü¸Á
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • GAP ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Á¦Ç°º°

  • ÁÖ¿ä µ¿Çâ
  • ½ÉÀåÆÇ¸· ±â±â
    • ¼ö¼ú¿ë ½ÉÀå ÆÇ¸·
    • °æÄ«Å×ÅÍ ½ÉÀå ÆÇ¸·
  • ȯÇü ¼ºÇü ¸µ
  • ¿ÀŬ·ç´õ ¹× µô¸®¹ö¸® ½Ã½ºÅÛ
  • ±âŸ Á¦Ç°

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ½Ã¼úº°

  • ÁÖ¿ä µ¿Çâ
  • ġȯ¼ú
    • ¿Ü°úÀû ´ëµ¿¸ÆÆÇ ġȯ¼ú(SAVR)
    • °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú(TAVR)
    • °æÄ«Å×ÅÍ ½Â¸ðÆÇ ġȯ¼ú(TMVR)
    • ±âŸ ġȯ¼ú
  • ¼öº¹¼ú
    • Left atrial appendage closure (LAAC)
    • Transcatheter mitral valve repair (TMVr)
    • Transcatheter tricuspid valve repair (TTVr)
    • ÆÇ¸· ¼ºÇü¼ú
    • ±âŸ ¼öº¹¼ú

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC)
  • ½ÉÀå Ä«Å×ÅÍ °Ë»ç½Ç
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • AtriCure, Inc.
  • Biomerics, LLC
  • Boston Scientific Corporation
  • Braile Biomedica
  • Cryolife Inc.
  • Edwards Lifesciences Corporation
  • JenaValve Technology, Inc.
  • Lepu Medical Technology(Beijing) Co.,Ltd.
  • LivaNova PLC
  • Medtronic plc
  • NuMed Inc.
LSH 24.04.03

Structural Heart Devices Market size is poised to expand at 8.8% CAGR between 2024 and 2032 due to the expanding application scope and continuous new product developments.

Beyond traditional procedures, such as valve replacements and repairs, structural heart devices are used for treating a wide range of conditions, including atrial septal defects (ASDs), patent foramen ovale (PFO), and left atrial appendage closures (LAAC). Moreover, the ongoing advancements in device technologies are leading to the development of novel materials, improved delivery systems, and enhanced imaging techniques. For instance, in March 2024, Abbott introduced the most recent version of its Navitor heart valve technology in the U.S. with several improvements over the last model. Such new product developments to offer improved efficacy, safety, and outcomes are fueling the demand for structural heart devices worldwide.

The industry is segmented into product, procedure, end-use, and region.

Based on product, the market share from the annuloplasty rings segment is projected to gain significant traction at 9.1% CAGR from 2024-2032. These rings play a vital role in surgical procedures for heart valve repair and replacement, particularly in mitral and tricuspid valve surgeries. The rising prevalence of valvular heart diseases coupled with the increasing adoption of minimally invasive surgical techniques will drive the demand for annuloplasty rings to provide structural support to the heart valves for improving their function and durability. Furthermore, advancements in ring designs, materials, and technologies are also propelling the segment growth.

With respect to end-use, the structural heart devices market from the cardiac catheterization labs segment generated considerable revenue in 2023 and is estimated to witness 9.1% growth rate through 2032. Cardiac catheterization labs are at the forefront of minimally invasive procedures for structural heart conditions, such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR). The increasing prevalence of cardiovascular diseases and the preference for less invasive treatment options are fueling the demand for structural heart devices in these specialized facilities.

Given the regional landscape, the Asia Pacific structural heart devices industry is set to exhibit 9.9% CAGR from 2024-2032 driven by the rising prevalence of cardiovascular diseases, coupled with the aging population and changing lifestyles. Moreover, the improving economic conditions and increasing healthcare expenditure are facilitating the adoption of advanced cardiac procedures across the region. As a result, countries including China, India, Japan, and South Korea are becoming significant hubs for structural heart device manufacturers. Advancements in healthcare infrastructure, access to sophisticated medical technologies, and the growing number of skilled healthcare professionals are further driving the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast calculations
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing burden of cardiovascular diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Favorable reimbursement scenario
      • 3.2.1.4 Rising preference for minimally invasive procedures
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stringent regulatory policies
      • 3.2.2.2 Potential complications and adverse events
  • 3.3 Growth potential analysis
  • 3.4 Porter's analysis
    • 3.4.1 Supplier power
    • 3.4.2 Buyer power
    • 3.4.3 Threat of new entrants
    • 3.4.4 Threat of substitutes
    • 3.4.5 Industry rivalry
  • 3.5 PESTEL analysis
  • 3.6 Pricing analysis, 2023
  • 3.7 Reimbursement scenario
  • 3.8 Regulatory landscape
  • 3.9 Technological landscape
  • 3.10 Future market trends
  • 3.11 GAP analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Heart valve devices
    • 5.2.1 Surgical heart valves
    • 5.2.2 Transcatheter heart valves
  • 5.3 Annuloplasty rings
  • 5.4 Occluders & delivery systems
  • 5.5 Other products

Chapter 6 Market Estimates and Forecast, By Procedure, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Replacement procedures
    • 6.2.1 Surgical aortic valve replacement (SAVR)
    • 6.2.2 Transcatheter aortic valve replacement (TAVR)
    • 6.2.3 Transcatheter mitral valve replacement (TMVR)
    • 6.2.4 Other replacement procedures
  • 6.3 Repair procedures
    • 6.3.1 Left atrial appendage closure (LAAC)
    • 6.3.2 Transcatheter mitral valve repair (TMVr)
    • 6.3.3 Transcatheter tricuspid valve repair (TTVr)
    • 6.3.4 Valvuloplasty
    • 6.3.5 Other repair procedures

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Cardiac catheterization labs
  • 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 AtriCure, Inc.
  • 9.3 Biomerics, LLC
  • 9.4 Boston Scientific Corporation
  • 9.5 Braile Biomedica
  • 9.6 Cryolife Inc.
  • 9.7 Edwards Lifesciences Corporation
  • 9.8 JenaValve Technology, Inc.
  • 9.9 Lepu Medical Technology(Beijing)Co.,Ltd.
  • 9.10 LivaNova PLC
  • 9.11 Medtronic plc
  • 9.12 NuMed Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦